The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans

키워드

참고문헌 (75)

1. "Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents living with HIV"[URL]
2. Kaplan JE, "Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America", MMWR Recomm Rep, 58(RR-4), pp.1~207 (2009)
3. Aberg JA, "Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America", Clin Infect Dis, 58, pp.e1~e34 (2014)
4. "European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. Version 8.2"[URL]
5. Mellors JW, "Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection", Ann Intern Med, 126, pp.946~954 (1997)
6. Egger M, "Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies", Lancet, 360, pp.119~129 (2002)
7. Hughes MD, "Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team", Ann Intern Med, 126, pp.929~938 (1997)
8. Marschner IC, "Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy", J Infect Dis, 177, pp.40~47 (1998)
9. Thiébaut R, "Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA)", AIDS, 14, pp.971~978 (2000)
10. Freedberg KA, "Initial assessment of patients infected with human immunodeficiency virus : the yield and cost of laboratory testing", J Acquir Immune Defic Syndr, 7, pp.1134~1140 (1994)
11. Samaras K, "Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy", J Acquir Immune Defic Syndr, 50, pp.499~505 (2009)
12. Antinori A, "Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy", Infection, 37, pp.270~282 (2009)
13. Gandhi RT, "Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen : implications for hepatitis B vaccine strategies", J Infect Dis, 191, pp.1435~1441 (2005)
14. Aberg JA, "Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America", Clin Infect Dis, 49, pp.651~681 (2009)
15. Schwarcz S, "Late diagnosis of HIV infection: trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS", J Acquir Immune Defic Syndr, 43, pp.491~494 (2006)
16. Battegay M, "Late presentation of HIV-infected individuals", Antivir Ther, 12, pp.841~851 (2007)
17. Palella FJ Jr, "Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study", J Acquir Immune Defic Syndr, 43, pp.27~34 (2006)
18. Mallal S, "HLA-B*5701 screening for hypersensitivity to abacavir", N Engl J Med, 358, pp.568~579 (2008)
19. Park WB, "Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?", Clin Infect Dis, 48, pp.365~367 (2009)
20. Saag M, "High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients", Clin Infect Dis, 46, pp.1111~1118 (2008)
21. Hammer SM, "Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel", JAMA, 296, pp.827~843 (2006)
22. 송준영, "치료 경험이 없는 HIV 감염자에서의 항바이러스제 일차 내성 분석: 한국HIV", AIDS 코호트 연구, 2009, pp.41(4), 230~232[DOI]
23. Bang JI, "Prevalence of primary antiretroviral resistance : trends in Korea", AIDS Res Hum Retroviruses, 24, pp.83~85 (2008)
24. 김서린, "치료력이 없는 HIV 감염환자에서 약제내성 빈도", 대한내과학회지, 73(3), pp.243~250 (2007), 대한내과학회
25. De Santis M, "Hemangiomas and other congenital malformations in infants exposed to antiretroviral therapy in utero", JAMA, 291, pp.305~ (2004)
26. Fundarò C, "Myelomeningocele in a child with intrauterine exposure to efavirenz", AIDS, 16, pp.299~300 (2002)
27. Ledergerber B, "AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy : the Swiss HIV Cohort Study", JAMA, 282, pp.2220~2226 (1999)
28. Smit C, "Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion", AIDS, 20, pp.741~749 (2006)
29. d'Arminio Monforte A, "The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy", Arch Intern Med, 165, pp.416~423 (2005)
30. Mocroft A, "Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group", Lancet, 352, pp.1725~1730 (1998)
31. Hogg RS, "Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy", JAMA, 286, pp.2568~2577 (2001)
32. Palella FJ Jr, "Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata", Ann Intern Med, 138, pp.620~626 (2003)
33. Baker JV, "CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection", AIDS, 22, pp.841~848 (2008)
34. When To Start Consortium, "Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients : a collaborative analysis of 18 HIV cohort studies", Lancet, 373, pp.1352~1363 (2009)
35. Strategies for Management of Antiretroviral Therapy(SMART)Study Group, "Major clinical outcomes in antiretroviral therapy(ART)-naive participants and in those not receiving ART at baseline in the SMART study", J Infect Dis, 197, pp.1133~1144 (2008)[DOI]
36. Cohen MS, "Prevention of HIV-1 infection with early antiretroviral therapy", N Engl J Med, 365, pp.493~505 (2011)
37. Arribas JR, "Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E", C, J Acquir Immune Defic Syndr, pp.2017, 75[DOI]
38. Sax PE, "Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy", N Engl J Med, 361, pp.2230~2240 (2009)
39. Smith KY, "Randomized, double-blind, placebo-matched, multicenter trial of abacavir", lamivudine or tenofovir, ritonavir for initial HIV treatment, pp.AIDS, 2009[DOI]
40. Arribas JR, "Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine", lamivudine and efavirenz in treatment-naive patients: 144-week analysis, 2008, pp.47, 74~78
41. Berenguer J, "Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903", Clin Infect Dis, 47, pp.1083~1092 (2008)
42. Raffi F, "Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial", Lancet Infect Dis, 13, pp.927~935 (2013)
43. Raffi F, "Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study", Lancet, 381, pp.735~743 (2013)
44. Walmsley S, "Brief report : dolutegravir plus abacavir", lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients : week 96 and week 144 results from the SINGLE randomized clinical trial, 2015, pp.70, 515~519
45. Molina JM, "Once-daily dolutegravir is superior to once-daily darunavir", ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO, 2014, pp.17(4 Suppl 3), 19490~
46. Rockstroh JK, "Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir", emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK, 2013, pp.63, 77~85
47. DeJesus E, "Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial", Lancet, 379, pp.2429~2438 (2012)
48. Wohl DA, "A randomized, double-blind comparison of single-tablet regimen elvitegravir", cobicistat, tenofovir DF versus single-tablet regimen efavirenz, pp.emtricitabine, tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results[DOI]
49. Clumeck N, "A randomized, double-blind comparison of single-tablet regimen elvitegravir", cobicistat, tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine, pp.tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results, J Acquir Immune Defic Syndr[DOI]
50. Zash R, "Neural-tube defects with dolutegravir treatment from the time of conception", N Engl J Med, 379, pp.979~981 (2018)
51. Zash R, "Surveillance for neural tube defects following antiretroviral exposure from conception", 22nd International AIDS Conference (2018)
52. Nelson MR, "Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine", tenofovir DF : pooled 96-week data from ECHO and THRIVE Studies, 2013, pp.14, 81~91
53. Molina JM, "Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial", Lancet, 378, pp.238~246 (2011)[DOI]
54. Riddler SA, "Class-sparing regimens for initial treatment of HIV-1 infection", N Engl J Med, 358, pp.2095~2106 (2008)
55. Orkin C, "Final 192-week efficacy and safety of once-daily darunavir", ritonavir compared with lopinavir, HIV Med, pp.2013, 14[DOI]
56. Molina JM, "Once-daily atazanavir", ritonavir compared with twice-daily lopinavir, J Acquir Immune Defic Syndr, pp.2010, 53[DOI]
57. Malan DR, "Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients", J Acquir Immune Defic Syndr, 47, pp.161~167 (2008)
58. "Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV"[URL]
59. Nettles RE, "Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART", JAMA, 293, pp.817~829 (2005)
60. Ledergerber B, "Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes", Lancet, 364, pp.51~62 (2004)
61. Peters MG, "Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127", Hepatology, 44, pp.1110~1116 (2006)
62. Matthews GV, "Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV", HBV coinfected individuals, 2009, pp.23, 1707~1715
63. de Vries-Sluijs TE, "Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus", Gastroenterology, 139, pp.1934~1941 (2010)
64. Pessôa MG, "Efficacy and safety of entecavir for chronic HBV in HIV", HBV coinfected patients receiving lamivudine as part of antiretroviral therapy, 2008, pp.22, 1779~1787
65. McMahon MA, "The HBV drug entecavir-effects on HIV-1 replication and resistance", N Engl J Med, 356, pp.2614~2621 (2007)
66. Dore GJ, "Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption", AIDS, 24, pp.857~865 (2010)
67. Verma S, "Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis?", BMC Res Notes, 1, pp.46~ (2008)
68. Ragni MV, "Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection", Haemophilia, 15, pp.552~558 (2009)
69. Macías J, "Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus", hepatitis C virus, 2009, pp.50, 1056~1063
70. Townsend CL, "Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006", AIDS, 22, pp.973~981 (2008)
71. Tubiana R, "Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies", ml at delivery : a case-control study nested in the French perinatal cohort(EPF-ANRS CO1), 2010, pp.50, 585~596
72. Ford N, "Safety of efavirenz in the first trimester of pregnancy : an updated systematic review and meta-analysis", AIDS, 25, pp.2301~2304 (2011)
73. de Ruiter A, "British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review)", HIV Med, 15(Suppl 4), pp.1~77 (2014)
74. "Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States"[URL]
75. Floridia M, "Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancy", HIV Clin Trials, 11, pp.303~311 (2010)

관련 논문AI추천